Brokerages Set Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) PT at $14.30

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $14.30.

VNDA has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday. Finally, Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th.

Vanda Pharmaceuticals Stock Up 3.0%

Shares of NASDAQ VNDA opened at $5.48 on Friday. The firm’s 50-day moving average is $6.07 and its two-hundred day moving average is $6.98. The company has a market capitalization of $329.51 million, a PE ratio of -1.35 and a beta of 0.60. Vanda Pharmaceuticals has a 12-month low of $4.14 and a 12-month high of $9.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.The business had revenue of $51.72 million for the quarter, compared to analysts’ expectations of $54.98 million. Equities analysts anticipate that Vanda Pharmaceuticals will post -2.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently modified their holdings of VNDA. Torren Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth about $25,000. Russell Investments Group Ltd. lifted its stake in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 5,328 shares during the period. Quarry LP acquired a new stake in Vanda Pharmaceuticals during the third quarter worth approximately $53,000. Cerity Partners LLC acquired a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $69,000. Finally, Boothbay Fund Management LLC acquired a new stake in Vanda Pharmaceuticals during the third quarter worth approximately $72,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.